#Kaposi sarcoma

The immune modulator Pomalyst led to remission in two thirds of people with AIDS-related KS.

Study suggests immune-based cancer therapies might be particularly beneficial for HIV-positive people.

Researchers analyzed autopsies among people with HIV who died in New York City since 1984.

The Office of HIV and AIDS Malignancy at the National Cancer Institute coordinates cancer and HIV research.

Treatment with checkpoint inhibitors appears safe and effective for HIV-positive people.

Researchers looked both at the first and second time people with HIV have been diagnosed with cancer.

Researchers looked both at the first and second time people with HIV have been diagnosed with cancer.

Six out of nine patients experienced cancer remission with Opdivo or Keytruda.

A speedy overview of the major scientific findings presented at the International AIDS Conference in Amsterdam (AIDS 2018)

Its decline after the advent of antiretroviral therapy did not extend to Black men in the South.

An estimated 7,760 HIV-positive U.S. residents were diagnosed with cancer in 2010.

Declining rates are expected for Kaposi sarcoma, non–Hodgkin lymphoma, cervical and lung cancer and Hodgkin lymphoma, among others.

However, older people with HIV have a lower rate of a few other cancers compared with the general population.

However, compared with the general population, HIV-positive individuals remain at higher risk for a slew of malignancies.